Tranquilizer Drugs Market to be driven by increased investment in research & development for new product innovation is expected to grow at a CAGR of 3.60% during the forecast period 2023 to 2032

Market Research Future (MRFR) has published a cooked research report on the “Global Tranquilizer Drugs Market” that contains information from 2018 to 2032. The tranquilizer drugs market is estimated to register a CAGR of 3.60% during the forecast period of 2023 to 2032.

Market Highlights

The global tranquilizer drugs market is accounted to register a CAGR of 3.60% during the forecast period and is estimated to reach USD 2.89 billion by 2032.

Rising cardiovascular disease incidences are a primary element driving the worldwide tranquilizer drugs market growth rate. Cardiovascular diseases are the primary cause of death in both developed and emerging economies. This will open up new potential for the worldwide tranquilizer drugs industry. Additionally, growing drug approvals and launches will accelerate the market's growth rate.

Key Players

MRFR recognizes the following companies as the key players in the global tranquilizer drugs market— AstraZeneca Plc. , Eli Lilly and Company, GlaxoSmithKline plc, Merck & Co., Inc., Pfizer, Inc., Johnson & Johnson, Bristol-Myers Squibb Company, Allergan, Sun Pharma and Abbott.

Segment Analysis

The global tranquilizer drugs market has been segmented based on major tranquilizers and minor tranquilizers.

On the basis of major tranquilizers, the market is segmented into Phenothiazine Derivatives, Butyrophenones, Thioxanthene Derivatives and Others. The butyrophenones segment was attributed to holding the largest market share in 2022 because it is used to treat schizophrenia and other psychoses, as well as symptoms of agitation, irritability, and delirium.

Based on minor tranquilizers, the global tranquilizer drugs market has been segmented into Benzodiazepine Derivatives, Propanediol Dicarbamate Derivatives, Cyclopyrrolone Derivatives and Others. The benzodiazepine derivatives was expected to hold the largest market share in 2022 because it produce muscle relaxation and sedation through central nervous system action.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Tranquilizer Drugs Market Research Report

 Regional Analysis

The global tranquilizer drugs market, based on region, has been divided into North America, Europe, Asia-Pacific, and Rest of the World. North America consists of the US and Canada. The Europe tranquilizer drugs market comprises Germany, France, the UK, Italy, Spain, and the Rest of Europe. The tranquilizer drugs market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the Rest of Asia-Pacific. The Rest of the World tranquilizer drugs market comprises the Middle East, Africa, and Latin America.

North America dominates the worldwide tranquilizer drugs market because of the increased acceptance of newer technologies and increased demand for disease-specific treatment. Furthermore, the increasing presence of major key players and rising healthcare expenditure will drive the market's growth rate within the area. Rising public and private sector initiatives to raise knowledge about various illnesses will boost the worldwide tranquilizer drugs market.

Moreover, the Europe market has been persistently growing over the forecast period due to the surging frequency of myocardial infection patients and rising government activities in this region. Furthermore, the development of healthcare infrastructure will accelerate the market's growth rate in this region.

Asia-Pacific region is growing at the fastest CAGR during the forecast period due to the huge number of patients suffering from psychological anguish, cancer, AIDS, and other chronic ailments. Additionally, the growth is also propelled by government policies and initiatives.

Furthermore, the Rest of the world's tranquilizer drugs market is divided into the Middle East, Africa, and Latin America. This growth is attributed to the region's Rising cardiovascular disease incidences production research and development. Government support, a rise in investor interest, and the viability of the technology in the sector are all contributing factors to the market expansion.

Key Findings of the Study

• The global face treatment market is expected to reach USD 2.89 billion by 2032, at a CAGR of 3.60% during the forecast period.


• The Asia-Pacific region accounted for the fastest-growing global market due to the increasing number of patients suffering from psychological anguish, cancer, AIDS, and other chronic ailments and government policies and initiatives.


• Based on minor tranquilizers, the global tranquilizer drugs market has been segmented into Benzodiazepine Derivatives, Propanediol Dicarbamate Derivatives, Cyclopyrrolone Derivatives and Others. The Benzodiazepine Derivatives was expected to hold the largest market share in 2022.


• AstraZeneca Plc., Eli Lilly and Company, GlaxoSmithKline plc, Merck & Co., Inc., Pfizer, Inc., Johnson & Johnson, Bristol-Myers Squibb Company, Allergan, Sun Pharma and Abbott are the key market players.